Intelligence Feed event · Equity · 2026-10-07

    Vaxcyte prices $1.0B concurrent offering of common stock and convertible notes

    Question

    Vaxcyte prices $1.0B concurrent offering of common stock and convertible notes

    Direct answer

    Vaxcyte completed the pricing of a $1.0 billion financing transaction split between equity and debt instruments. The company priced 7.4 million shares of common stock at $64.00 each, alongside pre-funded warrants. In addition, Vaxcyte issued $500 million of 1.50% convertible senior notes maturing in 2032. The capital raise bolsters cash balances for clinical development while creating near-term supply absorption in the shares.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Vaxcyte prices $1.0B concurrent offering of common stock and convertible notes”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/vaxcyte-prices-1-0b-concurrent-offering-of-common-stock-and-convertible-notes-8a5f66

    EQUITY
    Vaxcyte prices $1.0B concurrent offering of common stock and convertible notes
    Vaxcyte completed the pricing of a $1.0 billion financing transaction split between equity and debt instruments. The company priced 7.4 million shares of common stock at $64.00 each, alongside pre-funded warrants. In addition, Vaxcyte issued $500 million of 1.50% convertible senior notes maturing in 2032. The capital raise bolsters cash balances for clinical development while creating near-term supply absorption in the shares.
    PCVX
    Impact
    73
    OCT 7
    SIG
    92%
    PCVX
    Vaxcyte prices $1.0B concurrent offering of common stock and convertible notes
    Vaxcyte completed the pricing of a $1.0 billion financing transaction split between equity and debt instruments. The company priced 7.4 million shares of common stock at $64.00 each, alongside pre-funded warrants. In addition, Vaxcyte issued $500 million of 1.50% convertible senior notes maturing in 2032. The capital raise bolsters cash balances for clinical development while creating near-term supply absorption in the shares.
    → Share issuance of 7.4M shares at $64.00 creates immediate equity dilution while $500M in 1.50% convertible notes introduces future share overhang.
    Impact
    Vaxcyte completed the pricing of a $1.0 billion financing transaction split between equity and debt instruments. The company priced 7.4 million shares of common stock at $64.00 each, alongside pre-funded warrants. In addition, Vaxcyte issued $500 million of 1.50% convertible senior notes maturing in 2032. The capital raise bolsters cash balances for clinical development while creating near-term supply absorption in the shares.
    Affected
    PCVX
    Transmission
    Share issuance of 7.4M shares at $64.00 creates immediate equity dilution while $500M in 1.50% convertible notes introduces future share overhang.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    PCVXequity dilution and convertible arbitrage hedgingMixed1-5dVaxcyte announced pricing of $1 billion concurrent offerings at $64.00 per share.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    PCVXMixed66.96 2026-10-07-2.90%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month